<DOC>
	<DOCNO>NCT03055312</DOCNO>
	<brief_summary>Compare efficacy bicalutamide conventional chemotherapy ( Treatment Physician 's Choice , TPC ) first-line treatment AR positive metastatic triple negative breast</brief_summary>
	<brief_title>Bicalutamide Treatment Androgen Receptor ( AR ) Positive Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description>This phase III , Multi-center , prospective , randomized clinical trial . The objective compare efficacy bicalutamide conventional chemotherapy ( Treatment Physician 's Choice , TPC ) first-line treatment AR positive metastatic triple negative breast cancer.Primary endpoint 16-week clinical benefit rate ( CBR ) .By centre randomize group bicalutamide ( experimental Group ) TPC ( Control Group ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Age : 1870 year old , female Eastern Cooperative Oncology Group ( ECOG ) 0 1 Confirmed pathology organize cytology AR positive ( IHC：≧10 % ) triple negative breast cancer For first time recurrence newly diagnose advanced breast cancer , Diseasefree survival time 12 month Measurable disease per RECIST version 1.1 , immeasurably lesions bone metastasis After Recurrence receive cancer treatment Life expectancy least 6 month Signed date informed consent form ECOG score ≧2 Only brain metastasis meningeal metastasis Receiving antitumor treatment Heart , lung , liver , kidney , bone marrow , function badness</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>